110 Views

Mint Solutions bags Series A funds

Mint Solutions said Tuesday that it has secured 4.425 million euros in Series A financing. The investors included Life Sciences Partners and Seventure Partners. In conjunction with the funding, Anne Portwich of LSP and Eric de La Fortelle of Seventure Partners have been added to Mint Solutions’ board of directors. Mint Solutions is is a developer of MedEye, which helps patients get the right medication at the right time.

Middle Peak Raises $8.5M From Wellington, Seventure, Grunderfonds

Middle Peak Medical said it raised $8.5 million in a Series A financing in a deal co-led by Wellington Partners and Seventure Partners, along with seed investor High-Tech Gründerfonds Management GmbH. The money will fund development of Middle Peak’s technology for treating mitral valve disease

TxCell Raises $16M From InnoBio, Auriga, Seventure

TxCell SA said it raised $16 million in a third round of financing supported by the InnoBio fund, managed by CDC Entreprises, and existing shareholders Auriga Partners and Seventure Partners. InnoBio contributed about $7.8 million to the round.

RuiYi and arGEN-X Announce License Agreement

arGEN-X BV has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. arGEN-X is backed by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.

Domain Therapeutics Completes Financing Round

Domain Therapeutics has completed a 2 million euro ($2.5 million) financing round. The biopharmaceutical company is based in Strasbourg, France. Half of the funds have been provided by a new investor, Seventure Partners and the other half has been committed by another new investor, SODIV and Domain’s existing shareholders – AIRFI, IP Growth, Auriga and […]

arGEN-X Inks $37M Series B

arGEN-X, a biopharmaceutical company developing human monoclonal antibodies, has raised 27.5 million euro ($37 million) in Series B financing. OrbiMed Advisors and Seventure Partners co-led the round, which included participation from existing shareholders Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB. Mike Sheffery of OrbiMed will join the company’s board.

PhosphonicS Raises £3.5 Million

PhosphonicS, a UK-based developer of precious metal scavenger products, has raised £3.5 million in second-round funding. Seventure Partners led the round, and was joined by return backers like Regents Park Partners. PhosphonicS is a spinout from Queen Mary University of London.

Tradoria Raises Series B Round

Tradoria, a German developer of ecommerce solutions for small and mid-sized merchants, has raised €2 million in Series B funding. Seventure Partners led the round, and was joined by DuMont Venture.

BiancaMed Raises €6 Million

BiancaMed, a Dublin, Ireland-based developer of sleep monitoring technology for conditions like sleep apnea, has raised €6 million in second-round funding. Seventure Partners led the round, and was joined by return backers ePlanet, Enterprise Ireland and ResMed. Go4Ventures served as placement agent.

PEHUB Community

Join the 12506 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget